60 likes | 71 Views
DTx provides evidence-based treatments utilizing software, such as various mobile health applications, that may be used to supplement or replace conventional treatment method of an illnesses.
E N D
Digital Therapeutics (DTx) Market Global Industry Analysis, Size, Share, Analysis, Growth, Forecast 2020 - 2030 Trends, and TMR Research www.tmrresearch.com
Digital Therapeutics (DTx) Market 1MARKETOVERVIEW A greater focus on preventive healthcare, the need to reduce healthcare costs, more expenditure in digital therapies and increasing prevalence of avoidable chronic illnesses are all likely to drive the growth of the global digital therapeutics (DTx) market in the near future. DTx provides evidence-based treatments utilizing software, such as various mobile health applications, that may be used to supplement or replace conventional treatment method of an illnesses. TMR Research www.tmrresearch.com
Digital Therapeutics (DTx) Market 2KEY TRENDS Chronic disease's high incidence and prevalence rate is a serious problem for healthcare systems all over the world. Patients suffering from chronic illnesses challenge in terms of therapy, since biopsychic or psychosomatic variables frequently affect these patients. Patients must modify their behavior as part of this new self-care culture since chronic illnesses are typically linked uncertainties. provide a considerable with significant levels of TMR Research www.tmrresearch.com
Digital Therapeutics (DTx) Market 3REGIONAL ASSESSMENT North America is one of the prominent regions in the global digital therapeutics (DTx) market and the region is followed by Europe. Expansion of the market in North America is fueled by factors such as changes in the reimbursement system for digital therapeutics, augmented investments in digital therapeutics, regulatory initiatives to promotetechnicalbreakthroughs,andtheentryofnewstartups. TMR Research www.tmrresearch.com
Digital Therapeutics (DTx) Market 4COMPETITVE ANALYSIS One therapeutics (DTx) market is mentioned as below of the recent developments in the global digital In April 2021, US-based Welldoc Inc. and DexCom, Inc., developer of continuous glucose monitoring system, have teamed up to create a new product. This collaboration allowed BlueStar to offer Dexcom G6 CGM to individuals with Type 2 diabetes. This new product serves as a single platform for better health. TMR Research www.tmrresearch.com
TMR Research www.tmrresearch.com Sample Discount Check link in description